This sounds like an interesting opportunity.

Xcellomics is seeking novel, in vitro or ex vivo pathologically relevant cellular phenotypes that have the potential to be developed into small molecule High Content or CRISPR screens. We are encouraging members of the research community to submit proposals through the Xcellomics applications portal in the following disease areas….

Full details here https://www.xcellomics.com/calls

Xcellomics is a partnership between Exscientia and the University of Oxford Target Discovery Institute (TDI).